Method of treatment of subclinical mastitis in lactating cows

FIELD: veterinary medicine.

SUBSTANCE: method comprises the combined use of the tissue preparation on the 1, 3 and 5 days of treatment, and 15% solution of ASD-2f on tetrahydrovit at a dose of 10 ml intramuscularly on the 2, 4 and 6 days of treatment. The tissue preparation is used as biogenic stimulator aminoseleton which is administered subcutaneously into the upper third of the neck in increasing dose of 40-45-50 ml.

EFFECT: method is highly effective for treatment of subclinical mastitis in lactating cows.

3 tbl, 1 ex

 

The invention relates to veterinary medicine, in particular to the veterinary obstetrics, and can be used for the treatment of subclinical mastitis in cows.

Mastitis - inflammation of the mammary gland, occurring in response to adverse mechanical, physical, chemical and biological factors.

The main factors contributing to the emergence and development of mastitis are: technical imperfection of milking, the violation of technological regulations of machine milking of cows. First irritation occurs, which when repeated repetition of moves in aseptic inflammation - the hidden mastitis. Reduced General and local resistance, the conditions for penetration and multiplication of different opportunistic and pathogenic organisms causing inflammation occurring in subclinical or clinically severe form of mastitis (serous, catarrhal, purulent-catarrhal).

Currently, for the treatment of cows with mastitis are available a variety of drugs, including, as a rule, antimicrobial agents antibiotics, sulfa, nitrofuranovye and other means. But not all of them give the desired effect, which is primarily attributable to decreased sensitivity to him microflora causing mastitis. In this regard, there must the be the creation of new schemes and methods of treatment of subclinical mastitis in cows excluding the use of antimicrobial agents and reducing grading of milk to a minimum.

Known similar method for the treatment of mastitis in cows [EN 2320325 C1, A61K 31/00, 27.03.2008], introducing a complex preparation containing 2% solution of novocaine, antiseptic stimulant Dorogov second fraction (ASD-2F), Dimexidum and 40% glucose solution, in the following ratio of components, wt.%: the solution of novocaine 2% - 20-40; antiseptic stimulant Dorogov-2F - 1-3, dimexide - 13-15 and glucose 40% - the rest. The drug is heated to 37-38°C and injected intraperitoneally with the right hungry holes at a dose of 100-150 ml once a day 2-3 times in 48 hours prior to the recovery of the cow.

The disadvantage of this method is the complexity of the proposed integrated product, difficulty in making, as well as the complexity of the introduction.

Known similar method for the prevention and treatment of mastitis in cows [EN 2201758 C2, A61K 35/45, 10.04.2003], providing for the introduction of tissue preparation, which is used as the filtrate of the extract of the breast healthy animals, stable mannitol. With the preventive purpose of the drug is administered twice 20-30 and on the 10th day before calving, subcutaneously at a dose of 0.1-0.2 ml per kg of body weight. For therapeutic purposes in addition enter bacteriological in nademanee space at a dose of 25-30 ml twice with the interval of the m-24 hours.

The disadvantage of this method of treatment of mastitis in cows is low therapeutic efficiency (requires the introduction of additional bacteriological) and the fact that the drug is not commercially available.

Known similar method for the treatment of mastitis in cows [EN 2316329 C2, A61K 35/00, 27.04.2007], providing for the introduction of tissue preparation called "Vidor" (its composition, wt.%: ASD-2F - 4,0; Vivaton - 10,0; 0,9% isotonic solution of sodium chloride - the rest).

The disadvantage of this method of treatment of mastitis in cows is that only applies when mastitis viral etiology, not mass-produced, time-consuming when using, as in severe cases requires supplementation to all part of the udder.

Known analog - method of treatment of mastitis in cows using placenta denatured emulsified (PDE). PDE is used for the treatment and prevention of postpartum diseases in cows and pigs. Mastitis in cows it is injected subcutaneously at a dose of 20 ml every 48-72 hours 5-7 times [Guidance on the use of the Placenta denatured emulsified (PDE) for the prevention and treatment of endometritis and mastitis in cows and sows, with retention of placenta in cows, approved by the veterinary Department of the Ministry of agriculture of the Russian Federation on 25 June 2007 No. PTS-2-4.9/00209].

The disadvantage of this method of treatment of mastitis in cows is one which by its low efficiency and a long course of treatment (10-21 days).

The closest analogue prototype is a method of treatment of subclinical mastitis in lactating cows [EN 2441660 C1, AC 35/50, 10.02.2012], which consists in the joint application of the two nutrients PDE and a 15% aqueous solution of ASD-2F on tetrahedrite. 1, 3 and 5 days of treatment, patients of subclinical mastitis in animals injected subcutaneously PDE in a dose of 20 ml per animal, and at 2, 4 and 6 days intramuscularly 15% ASD-2F on tetrahedrite in the dose of 10 ml

However, this method is not sufficiently effective.

The technical result of the invention is to improve the efficiency of treatment of subclinical mastitis in cows.

The technical result is achieved in that in the method of treatment of subclinical mastitis in lactating cows, including the combined use of tissue preparation on 1, 3 and 5 days of treatment and a 15% aqueous solution of ASD-2F on tetrahedrite in the dose of 10 ml intramuscularly at 2, 4 and 6 days of treatment, according to the invention, as tissue preparation using biogenic stimulator aminosilicone, which is injected subcutaneously in the upper third of the neck in increasing the dose 40-45-50 ml.

Compared with the prototype the main feature of the invention is the introduction into the treatment of biogenic stimulator aminosilicone instead of PDE.

Aminosilicone tissue preparation obtained from the spleen using chriopractor the cation. This drug is used for immunodeficiency various etiologies. It is known that biologically active substances that enhance cellular and humoral immunity, see the organs of the immune system of animals, including the spleen. The cells of the body produce opsonins (tuftsin, fibronectin and others), a large complex of cytokines (Il-1, Il-2, Il-3, Il-4, Il-5, Il-6, Il-7, Il-8, Il-10, Il-12, Il-15, Il-18, TNF-alpha, granulocyte-macrophage colony-stimulating factor, IFN-γ, IFN-α), vasoactive putting peptide, growth factor, hepatocyte or dispersing factor (HGF/SF), splenic-derived growth factor (SDGF).

ASD-2F - antiseptic-stimulator Dorogov is a product of the destructive distillation of raw materials of animal origin. In its composition contains compounds with sulfhydryl group, derivatives of aliphatic amines, carboxylic acids, aliphatic and cyclic hydrocarbons, derivatives of amides and water. In appearance the product is a liquid from yellow to dark red color with a specific smell, well miscible with water. ASD-2F oral application has an activating effect on the Central and autonomic nervous system, stimulates motor activity of the gastrointestinal tract, the secretion of digestive glands, increases the activity of pisew is satisfactory and tissue enzymes improves the penetration of ions of Na+and K+through cell membranes, helps normalize digestion, absorption of nutrients and increase the natural resistance of the organism. Assign ASD-2F agricultural animals for therapeutic and preventive purposes in diseases of the gastrointestinal tract, respiratory, urinary tract, lesions of the skin, metabolic disorders, to stimulate the activity of the Central and autonomic system, increasing the natural resistance of the weak and sick animals. Milk of dairy cows after drug use without restriction, in the case of the forced slaughter of the animal meat use without restriction.

Tetrahydrof - medicinal products containing as active ingredients vitamins a, D, E and C. Vitamin a is involved in phosphate, carbohydrate, lipid metabolism, regulates oxidative processes, the growth of epithelial tissues, including the epithelium of the mammary gland. Vitamin D is involved in the regulation of energy and mineral exchanges, promotes the absorption of calcium and phosphorus. Vitamin E is involved in the regulation of carbohydrate and lipid metabolism, oxidative reactions in the body. Vitamin C is an important factor in normal growth and increases the protective functions of the organism (lenova of the Imperial family, Maltsev K. L., Yaremenko N. A. Veterinary medicines in Russia. The Handbook. M: Selhozizdat, 2004. Including 2 - n-68-69).

Check the efficiency of the method of treatment of mastitis in cows during lactation conducted on cows, belonging to JSC "JV Vanoverbeke" Voronezh region.

The essence of the technical solution illustrated in the examples.

Studies performed on 46 cows with subclinical mastitis. Cows in the first group (n=10) treatment was not subjected, animals of the second group (n=10) were subjected to treatment with ASD-2F and PDE (base case): 1-3-5 days) was subcutaneously injected PDE 20 ml, 2-4-6 days intramuscularly 15% solution of ASD-2F on tetrahedrite in the dose of 10 ml Animal-third (experimental) group (n=26) 1-3-5 days subcutaneously injected aminosilicone in increasing doses: 40-45-50 ml, and 3-4-6 days intramuscularly 15%th solution ASD-2F on tetrahedrite in the dose of 10 ml

Before treatment from 5 cows from each group and 5 days after treatment took blood samples for morphological and biochemical studies. In addition, before, during treatment (within 48; 96 and 120 hours) and 5-7 days after the end of treatment performed studies evaluating the physico-chemical properties of milk (mass fraction of protein, fat, density, number of somatic cells).

Efficacy of treatment of subclinical mastitis in cows is presented in the tables is 1.

It is established that in the control group during the observation period samoistselenie no animal has not come, and 3 (30,0%) cows with subclinical inflammation has passed in clinical form.

The efficiency of the joint application of the placenta emulsified denatured and 15%-aqueous solution of ASD-2F on tetrahedrite with subclinical mastitis was 70,0%.

Table 1
Therapeutic efficacy of complex treatment of subclinical mastitis in cows
The treatmentTreatedRecoveredLeft sick
cowssharescows%shares%cows%shares%
Control (without treatment)1012--- -10100,012100,0
PDE+ASD-2F (positive control)1013770,0969,2330,0430,8
Aminosilicone + ASD-2F26312284,62787,1415,4412,9

The best therapeutic effect was achieved with the complex use of aminosilicone and 15% ASD-2F on tetrahedrite to 84.6%, which is 14.6% more than when using PDE and ASD-2F.

The recovery of the cows was accompanied by stabilization of a number of indicators of homeostasis (table.2).

Table 2
Indicators geomorphological and biochemical status of cows before and after integrated the treatment of subclinical mastitis
Indicators, units of measurementAminosilicone+ASD-2FPDE+ASD-2F
before the treatmentafter the treatmentbefore the treatmentafter the treatment
Erythrocytes, 1012/l5,8±0,15,9±0,25,9±0,45,9±0,3
Leukocytes, 109/l8,2±0,77,9±0,38,1±1,27,8±0,3

Neutrophils,% stab1,8±0,20,6±0,012,1±0,20,4±0,0
segmented31,2±2,826,6±2,131,5±2,725,3±0,8
Eosinophils, %14,4±1,28,2±0,412,3±0,88,1±1,8
Basophils, %----
Lymphocytes, %55,6±1,961,0±3,158,1±5,661,8±3,3
Monocytes, %3,4±0,43,4±0,50,0±0,02,0±0,6
Platelets 109l380,0±51,7319,6±of 58.9445,2±84,6402,0±74,3
Hematocrit, %27,9±1,528,2±1,225,8±1,826,8±8,4
Total protein, g/l81,2±0,3to 82.9±0,387,4±3,2of 87.8±1,2
Albumin, %54,4±7,840,2±1,754,2±2,738,9±0,9
α-globulins, %10,4±0,711,6±0,60,3±0,6 12,6±0,1
β-globulins, %17,6±0,820,1±0,916,5±0,620,3±0,6
γ-globulins, %17,6±1,227,1±0,719,0±2,529,3±1,0
Overall immunol, g/l28,5±1,727,7±2,730,8±3,730,8±1,9
BASK, %64,9±5,769,9±13,862,1±0,967,9±10,2
CARESSES, mg %0,282±0,030,336±0,030,286±0,010,222±0,03
PHI, M. K./fagozyt5,7±0,57,3±0,45,9±0,36,5±0,5
FC, M. K./act. phage7,3±0.59,3±0,87,6±0,68,6±0,4
AAO, % 44,7±1,748,8±3,345,74±1,9
HMM μm/l1,9±0,41,3±0,11,8±0,41,3±0,2

So, in cows after treatment with application of aminosilicone and ASD-2F marked decrease in the number of platelets by 15.9% (P<0.05), and band neutrophils 3.0 times (P<0,001), segmented neutrophils 14.7% (P<0.05), and eosinophils 1.8 times (P<0,001), the amount of albumin 26.1% (P<0,001), malondialdehyde by 31.6%, increased phagocytic activity 13.9%, phagocytic index of 28.0%, phagocytic number of 27.3%, the antioxidant activity of the blood by 9.1%, while increasing the number of lymphocytes 9.7%, α-globulin 11.5%, β-globulin by 14.2% (P<0,001), γ-globulin by 53.9% (P<0,001), bactericidal and lysozyme activity of serum shelter 7.7% and 19.1%, respectively.

Similar positive changes in biochemical and immunological status marked when using the placenta emulsified denatured and ASD-2F.

It is established that treatment of cows aminosilicones in conjunction with the ASD-2F and PDE with ASD-2F showed a positive influence on the qualitative composition of the milk (table.3).

Table 3
Indicators of udder secretions of cows in recovered animals before and after complex treatment
IndicatorsBefore the treatmentDuring the treatmentAfter the treatment
After 48 hoursAfter 96 hoursAfter 120 hours
Control (without treatment)
1. Mass fraction of protein, %2,80±0,062,64±0,112,47±0,152,39±0,172,32±0,11
2. Fat content, %3,17±0,163,12±0,222,78±0,102,82±0,182,94±0,19
3. Density1025,7±0,211025,0±0,761024,6±0,491024,9±0,371024,3±0,58
4. The content of SC, you/ml3210,6±259,5484,8±924,2 3988,0±662,84121,3±4323890,3±392, 7
PDE+ASD-2F
1. Mass fraction of protein, %2,69±0,132,73±0,092,81±0,073,02±0,063,03±0,06
2. Fat content, %2,98±0,21is 3.08±0,213,36±0,143,98±0,124,01±0,18
3. Density1025,6±0,71025,9±0,81026,8±0,41027,8±0,5of 1028.1±0,4
4. The content of SC, you/ml4032,8±12723432,3±763,91685,2±548,5959,3±172,4854,2±100,9
Aminosilicone+ASD-2F
1. Mass fraction of protein, %2,93±0,122,86±0,093.04 from±0,12is 3.08±0,103,19±,12
2. Fat content, %3,15±0,173,35±0,143,56±0,084,12±0,334,22±0,12
3. Density1025,2±0,821026,2±0,491027,0±0,491028,8±0,411028,7±0,56
4. The content of SC, you/ml4590,6±702,53028,4±338,31173,2±362,0813,7±145,8706,8±100,3

In terms of quality it met the requirements of the first grade according to GOST №52045-2003 and the Federal law "Technical regulations for milk and dairy products" at the end of treatment.

Thus, an effective method for the treatment of subclinical mastitis in lactating cows, including the use of two nutrients - aminosilicone and 15%-aqueous solution of ASD-2F on tetrahedrite.

The method of treatment of subclinical mastitis in lactating cows, including the combined use of tissue preparation on 1, 3 and 5 days of treatment and a 15% aqueous solution of ASD-2F on tetrahedrite in the dose of 10 ml intramuscularly at 2, 4 and 6 days of treatment, distinguish the different topics as tissue preparation using biogenic stimulator aminosilicone, which is injected subcutaneously in the upper third of the neck in increasing the dose 40-45-50 ml.



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of animals with postpartum endometritis.

4 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of chemotherapeutic agents. The chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of endometritis in animals.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm.

EFFECT: inventions provide the effective cleansing of the uterine cavity from infected and necrotised tissues with improved comfort and safety of the procedure with using no endoscopic equipment, cervical dilation manipulations and uterine pre-probing.

2 cl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, particularly to an agent for treating and preventing endometritis in animals. The substance of the invention consists as follows. Novocaine 0.5 g is dissolved in distilled water 1 l, and the following preparations are dissolved in a solution of Novocaine 250 mg: powdered metronidazole 4.0 g is dissolved in Novocaine 250 ml; powdered ciprofloxacin 2.0 g is dissolved in Novocaine 250 ml; powdered Doxycycline 1.0 g is dissolved in Novocaine 250 ml; powdered tavegil 2.5 g is dissolved in Novocaine 250 ml; all the ingredients are combined to prepare the agent in an amount of 1 litre for treating and preventing endometritis in animals.

EFFECT: invention provides the pronounced anti-inflammatory and antimicrobial effect of a broad spectrum of action combined with reducing the body response to histamine, relieving smooth muscle spasm and reducing capillary penetration.

5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.

EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.

4 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating and managing the pregnant women suffering drug-induced hepatitis. Establishing a diagnosis of drug-induced hepatitis requires oral administration of the herbal hepatoprotectors Carsil, or Hepabene, or the vitamin-free essential phospholipids Eslidin per os or Essentiale forte N intravenously, per os in standard doses with a cessation of any other drug-induced therapy, in the 1st trimester of pregnancy in case of observing a symptom-free increase of transaminase activity within 3 normal values and no counter-indications. In the 2nd trimester, a serum transaminase level up to 5 normal values requires prescribing ademetionine 400 mg intravenously N 7-10, then per os 1,600 mg/day. The therapeutic course makes 1 month. Ademetionine 800 mg intravenously N 10 + ursodeoxycholic acid 12 mg/kg/day are prescribed if observing the daily serum transaminase level of 5 to 10 normal values. Prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 12 mg/kg/day + prednisolone 90 mg/day is used for the daily serum transaminase level of more than 10 normal values. In the 3rd trimester, the daily serum transaminase level of below 5 normal values requires administering ademetionine 800 mg/day intravenously N10 + ursodeoxycholic acid 13 mg/kg/day. The transaminase level of 5 to 10 normal values requires prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 13 mg/kg/day + prednisolone 90 mg/day intravenously. A progressive increase of the daily transaminase level of above 10 normal values with underlying therapy with ademetionine 800 mg/day intravenously, ursodeoxycholic acid 13 mg/kg/day, prednisolone 120 mg/day intravenously with 3 days expected, a decrease of the daily transaminase level or a stabilization thereof are accompanied by continuing the therapy with the progression follow-up, including hepatic cytolysis values - an increase of the hepatic cytolysis values; an increase thereof is accompanied by prescribing the adequate therapy. The postpartum therapy is continued completely until liver function tests are normalised.

EFFECT: method enables preventing the pregnancy complications ensured by the timely diagnosis of drug-induced hepatitis in the pregnant women, the adequate drug-induced therapy differentiated by gestational age and a degree of manifestation of hepatic cytolysis and aiming at reducing a hepatic pathological process.

6 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.

EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.

2 cl

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary medicine and is intended for treatment of mastitis in sheep. method includes introduction of medication, containing antibiotic and chemical therapeutic substance, at the background of subcutaneous introduction of oxytocin in dose 10 U two times with 12-hour interval and above-udder novocaine blockade in accordance with D.D.Logvinov, by double introduction of 0.25% novocaine solution in dose 0.5 ml per 1 kg of body weight, with 48-hour interval. Used is preparation, which contains antibiotic norfloxacin as antimicrobial preparation, and dioxydin as chemical therapeutic substance, and additionally 1,2-propyleneflycol, polyvinylpyrrolidone low-molecular, disodium salt of tetraacetic acid ethylenediamine (trilon B), hydrochloric acid (0.1 mol/l) to pH 4.5, water for injections with the following component ratio, wt %: dioxydin - 1.0; norfloxacin - 5.0; 1,2-propyleneflycol - 19.8; polyvinylpyrrolidone low-molecular - 0.2; disodium salt of tetraacetic acid ethylenediamine (trilon B) - 0.01; hydrochloric acid (0.1 mol/l) to pH 4.5-5.5; water for injections - to 100.0. Preparation is introduced intramuscularly in dose o.1 ml/kg of body weight two times per day until clinical recovery, for all forms of mastitis.

EFFECT: claimed invention makes it possible to provide expressed therapeutic effect.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at treating subclinical mastitis in cows. The method involves intracisternal administration of an activated physiologic saline. The activated physiologic saline is administered in the concentration of 600 mg/l in a dose of 20 ml after afternoon milking three days running. Additionally Trivyt 10 ml is intramuscularly injected on the first therapeutic day.

EFFECT: using the declared invention enables more effective treatment and reduced period of recovery.

2 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: therapeutic agent is used as N,N-dimethylamino-prolinamide of oleic acid of the formula 1 , which is used as the aqueous solutions of its salts with pharmacologically acceptable acids.

EFFECT: high therapeutic effect in treatment of endometritis of animals.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: mesenchymal stem cells are introduced into superior and inferior alveolar processes within roots of teeth. Herewith, 500-600 thousand cells are introduced into the superior alveolar process within the root of incisors, 800 thousand - 1 million cells - into the root of canine teeth, 1 million - 1 million 200 thousand cells into the root of premolar and molar teeth. Besides, 500-700 thousand cells are introduced into the inferior alveolar process within the root of incisors, 800 thousand - 1 million cells - into the root of canine teeth, 1 million - 1 million 200 thousand cells into the root of premolar and molar teeth. The therapeutic course involves 5-7 introductions every 2-3 weeks.

EFFECT: effective treatment of the disease, easier effect and reduced injuries.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely to cell transplantology for the regeneration of a bone tissue in surgical treatment of destructive, degenerative-dystrophic, traumatic or congenital affections of the bone tissue. A biotransplant contains a mixture of autologous multipotent mesenchymal stromal cells, cultivated in standard conditions, and multipotent mesenchymal stromal cells, differentiated in the osteogenic direction, taken in a weight ratio of 1:1 and in quantity of 107 cells per 1 g of the weight of a matrix-carrier, which has in the basis of its structure a collagen-mineral complex, identical in the composition to natural bone material. A method of the biotransplant obtaining is based on the application of the culture medium AdvanceSTEMTM/Antibiotic/Antimycotic Solution 100x with an addition of 10% of autologous serum of the patient's blood.

EFFECT: technical result of the invention consists in the provision of active angiogenesis with the formation of small capillaries, medium and large mature vessels in a young bone tissue together with the preservation of its osteoinductive properties; elimination of a risk of the immune response and an infection transmission caused by the application of embryonic calf serum; reduction of terms of the bone tissue recovery and its vascularisation.

2 cl, 2 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for antitumour immunotherapy. For this purpose, dendritic cells (DC), obtained from a patient's skin, spleen, bone marrow, thymus, lymph nodes, umbilical blood or peripheral blood (autologous DC) are introduced to the patient, with DC being introduced to the patient step-by-step. At the first stage the introduction of mature allogenic DC, loaded with a tumourspecific antigen, maturation of which is realised ex vivo, is performed. At the second stage not less than 24 hours, but not more than 120 hours after the first stage the re-introduction of allogenc DC is realised simultaneously with the introduction of immature autologous DC in situ in a tumour, with the tumour being subjected to an ablation impact preliminarily or simultaneously with DC introduction.

EFFECT: application of the claimed method makes it possible to achieve an increased immune response by the introduction of a two-component immune agent, which consists of a sensitising dose of allogenous mature cells and a therapeutic dose of immature DC, with 10% of the therapeutic DC dose being sufficient for sensitisation.

2 cl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: method of comprehensive treatment of cows with postpartum endometritis comprises repeated subcutaneous injection of preparation of general stimulating nonspecific therapy in conjunction with symptomatic and etiotropic preparations, and the preparation of general stimulating nonspecific therapy is used as tissue biostimulant from the spleen, which is administered subcutaneously five times with an interval between injections of 48÷72 hours with increasing doses of 30, 35, 40, 45 and 50 ml.

EFFECT: enhancing the therapeutic efficacy of treatment of cows with postpartum endometritis, reducing insemination index and duration of infertility.

3 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intracisternal administration of masticef at a dose of 5 ml with 24-hour intervals 2-4 times. The biogenic stimulator is used as a preparation obtained from pig spleen (BSS) by ultrasonic homogenisation, heating the homogenate, and its cooling, supernatant precipitation followed by removal of ballast proteins by centrifugation or ultrafiltration. The biogenic stimulator is administered subcutaneously in the upper third part of the neck in 1-3-5-7 days of treatment at a dose of 30-35-40-45 ml, respectively.

EFFECT: method enables to increase the effectiveness of treatment of all forms of mastitis in cows, to the reduce treatment time, and to reduce the term of milk rejection.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: what is applied is a stocking coating of an autogenous bone with a patient's platelet-rich plasma. Bone marrow aspirate from the patient's ilium and/or mesenchymal stromal cell autoculture prepared of the aspirate by culturing in vitro are injected under the coating layer into the autogenous bones. The autogenous bones are placed tightly in the bone defect to cover the defect area with adjacent soft tissues.

EFFECT: complete and effective synthesis of the bone tissue continuity by creating conditions of proliferative process isolation and osteoresorption process deceleration in the autogenous bone with no undesired immunological responses in the plasty area.

1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, and concerns a method for cardiac function recovery following acute myocardial infarction with infarction involvement, wherein the method involves introducing into an individual a non-swelling, recovered population of autogenous mononuclear cells enriched with CD34+ cells containing a subpopulation, at least 0.5×106 of high-active CD34+ cells expressing XCR-4 possessing CXCR-4 mediated chemotactic activity and shifting in response to SDF-1; using the pharmaceutical composition for preparing a therapeutic agent for the cardiac function recovery in the individual after acute myocardial infarction with an infarction inflammation, wherein the pharmaceutical composition contains the above recovered population of the autogenous mononuclear cells.

EFFECT: group of inventions provides less infarction involvements due to preventing cardiomyocyte loss following acute myocardial infarction by improving perfusion and preventing apoptosis.

78 cl, 13 ex, 4 dwg, 36 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to transplantology, and may be used for treating graft-versus-host disease (GVHD). That is ensured by introducing pluripotent cells, other than embryo stem cells, embryo germ-line cells, germ-line cells into an individual. The cells may differentiate in one cell type of any of at least two embyo lines - endodermal, ectodermal and mesodermal. The cells express telomerase; they are allogenic for the individual and promote the negative immune response. The group of inventions also refers to the above cells which are grown and processed during 10 to 40 cycles of cell duplication in a culture, and then specific markers (oct-3/4, rex-1 and rox-1) are expressed.

EFFECT: method enables using the pluripotent mature precursor cells additionally for immune suppression for transplantation.

21 cl, 10 dwg, 12 ex

Immunomodulator // 2497514

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents an immunomodulator for treating chronic hepatitis, hepatic cancer, lymphatic sarcoma, chronic leukemia, and for improving the functions of liver and blood-forming organs, for enhancing the immunobiological body characteristics, prepared by mixing 1000 ml of an aqueous infusion of sandy everlasting blossom, pepper mint herb and chicory herb with 50 ml of bovine serum containing leukaemia oncovirus antibodies, 20 ml of wild rosemary infusion, 40 g of ascorbic acid, 2 g of sorbic acid, 0.2 g of folic acid until the ingredients are dissolved completely, with adding 60 g of liver powder, 30 g of lymphatic node powder, 30 g of young bovine spleen powder; the prepared solution is settled at room temperature for 24 hours, then kept at a boiling water bath for 30 minutes and cooled for 6-8 hours at room temperature; the settled solution is filtered, wherein the aqueous herbal solution is prepared by mixing equal proportions of the separately prepared aqueous infusions of 40 g of pepper mint herb in 1000 ml of water, 30 g of sandy everlasting blossom in 1000 ml of water and 30 g of chicory herb in 1000 ml of water, while the wild rosemary infusion is prepared by infusing 60 g of ground wild rosemary blossom in 1000 ml of 70% purified ethanol.

EFFECT: invention provides creating the high-efficacy agent and reducing the length of treatment.

FIELD: biotechnologies.

SUBSTANCE: method is proposed to extract stem cells, including whirling of heparinised bone marrow with hydroxyethyl starch at the ratio of source ingredients of 1:2 with speed of 700g for 15 min. in the closed system of three haematological containers connected to each other with tubes with subsequent removal of fat admixtures and plasma into the container No.1, transfer of the mononuclear fraction of bone marrow, a part of supernatant and erythrocytes adjoining the interface of two media into the container No.2. Sludged erythrocytes and bone fragments remain in the main container, whirling of the produced sample with the speed of 900g for 15 min. in the container No.2 to produce cell material for intravascular introduction, at the same time after the specified whirling a part of supernatant is removed into the container No.1 without unsealing of the system.

EFFECT: production of paracrine effect of bone marrow mononuclear cells and provision of safety.

1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention provides a method of encapsulating antiseptic-stimulator Dorogova (ASD) fraction 2. The method is a physical-chemical non-solvent deposition method. When carrying out the method, the cladding of the microcapsules used is sodium alginate and the precipitation agent is carbon tetrachloride.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

Up!